Initially the pharmaceutical company ‘ran the numbers without those nine, and the result fell just short of statistical significance, at which point eight of the subjects were added back into the analysis, improving the statistics enough to make the results significant—the problem was later hidden in the submission to the FDA ... ’ 41 .
← all excerpts
Corporations, high-stakes biomedical research, and research misconduct: yes they can (and sometimes do).
1
—
—